News | October 23, 2019

ARVINAS PRESENTS A PLATFORM UPDATE, INCLUDING INITIAL DATA FROM THE FIRST TWO CLINICAL TRIALS OF PROTAC® TARGETED PROTEIN DEGRADERS -Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally...

News | November 6, 2019

ARVINAS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the...

News | July 29, 2019

ARVINAS APPOINTS RONALD PECK, M.D. AS CHIEF MEDICAL OFFICER NEW HAVEN, Conn., July 29, 2019 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today the...

News | May 29, 2019

ARVINAS RECEIVES FAST TRACK DESIGNATION FOR ITS TARGETED PROTEIN DEGRADER ARV-110 AS A TREATMENT FOR MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ARV-110 is Arvinas’ first clinical-stage drug in the innovative field of targeted protein degradation,...